This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Citi Sticks to Its Buy Rating for Stryker (SYK)

Tipranks - Tipranks - Fri May 29, 6:36AM CDT

In a report released today, Joanne Wuensch from Citi reiterated a Buy rating on Stryker, with a price target of $385.00.

Memorial Day Sale – Claim 70% Off TipRanks

According to TipRanks, Wuensch is a 2-star analyst with an average return of 0.1% and a 50.41% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific, Integra Lifesciences, and Stryker.

Stryker has an analyst consensus of Strong Buy, with a price target consensus of $391.67.

See today’s best-performing stocks on TipRanks >>

Based on Stryker’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.02 billion and a net profit of $745 million. In comparison, last year the company earned a revenue of $5.87 billion and had a net profit of $654 million

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Earlier this month, M Kathryn Fink, the VP, Chief HR Officer of SYK sold 8,720.00 shares for a total of $2,473,719.80.

Read More on SYK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).